And as you point out, there is a large market of consumers who need this in wealthy countries, which should mean normal market incentives to develop drugs apply.
The 1bn is not being spent very well by the NIH. A lot of it went to organisations without the necessary infrastructure or expertise. They’re not conducting the necessary research to determine viral persistence.
The planned trials by the NIH are not very exciting, and are going slow.
The “private venture” is the organisation I’m affiliated with. It has a funding gap of ~80 million at the moment and is primarily funding constrained. I’ll write more about LCRI in a new post soon :)
Very sorry to hear you have long covid, I hope you feel better soon.
I’m personally unconvinced that this is a neglected area.
Over $1bn is committed to researching this, with public and private initiatives planned. https://www.science.org/content/article/new-private-venture-tackles-riddle-long-covid-and-aims-test-treatments-quickly
And as you point out, there is a large market of consumers who need this in wealthy countries, which should mean normal market incentives to develop drugs apply.
Hey, thanks for the engagement.
The 1bn is not being spent very well by the NIH. A lot of it went to organisations without the necessary infrastructure or expertise. They’re not conducting the necessary research to determine viral persistence.
The planned trials by the NIH are not very exciting, and are going slow.
The “private venture” is the organisation I’m affiliated with. It has a funding gap of ~80 million at the moment and is primarily funding constrained. I’ll write more about LCRI in a new post soon :)